Navigation Links
Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1

LEBANON, N.J., May 28 /PRNewswire/ -- Orphan Therapeutics today announced that it has begun submission of the rolling LUCASSIN(R) (terlipressin) New Drug Application (NDA) for the treatment of hepatorenal syndrome (HRS) type 1 in patients with late-stage liver cirrhosis. LUCASSIN(R) had previously been granted orphan status and fast track designation for this indication by the U.S. Food and Drug Administration (FDA). Currently no drug is approved in the U.S. to treat HRS type 1, a rare and life-threatening condition in late-stage liver disease.

The LUCASSIN(R) rolling NDA submission is based on the results from OT-0401,(1) a randomized, double-blind, multi-center, placebo-controlled Phase III study in 112 patients with HRS type 1 conducted by Orphan Therapeutics, and is independently supported by TAHRS,(2) a second randomized, multi-center, controlled study in 46 patients coordinated by the University of Barcelona. Orphan Therapeutics holds exclusive rights to the TAHRS data for the NDA submission.

"We are pleased to report that, coinciding with the start of our rolling NDA for LUCASSIN(R), the two HRS studies, OT-0401 and TAHRS, have been published in the May 2008 issue of Gastroenterology," said Peter Teuber, president of Orphan Therapeutics. "I would like to thank all authors, investigators and members of the LUCASSIN(R) team for their contributions to these two landmark trials, which together represent the largest number of HRS patients studied in a randomized and controlled study design to-date."

The rolling submission process enables companies that have been granted fast track designation to submit sections of the NDA to the FDA as they become available. The FDA grants fast track status to drug candidates that treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Terlipressin received orphan drug designation in October 2004 and fast track status in April 2005 for treatment of HRS type 1.

(1) Sanyal 2008: Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F,

Rossaro L, Appenrodt B, et al. A randomized, prospective,

double-blind, placebo controlled trial of terlipressin for type 1

hepatorenal syndrome. Gastroenterology. 2008;134:1360-1368.

(2) Martin-Llahi 2008: Martin-Llahi M, Pepin M-N, Guevara M, Diaz, F,

Torre A, Monescillo A, et al. Terlipressin and albumin vs albumin in

patients with cirrhosis and hepatorenal syndrome: a randomized study.

Gastroenterology. 2008;134:1352-1359


Hepatorenal syndrome (HRS) is the progressive development of renal dysfunction in patients with late stage liver cirrhosis without any other causes of renal failure. It is likely caused by a very low blood flow through the kidneys, and two types have been described. HRS type 1 is characterized by rapid renal failure with a high mortality rate that exceeds 80% within three months. HRS type 2 represents a less aggressive form with longer survival.

The only potentially curative treatment for HRS and its underlying end- stage liver disease is liver transplantation, provided that the patient is a suitable candidate for transplantation and survives until a transplant is available. However, many patients may not receive a new liver, further supporting the need for alternate therapy options.

ABOUT LUCASSIN(R) (terlipressin)

LUCASSIN(R) (terlipressin) is a synthetic vasopressin analogue that acts via the vasopressin V1 receptor as a systemic vasoconstrictor, resulting in an increase in effective arterial volume and improved renal blood flow in patients with HRS. Terlipressin is not approved by the FDA for use in the U.S. Outside the U.S., terlipressin has been available for over two decades. It has been a standard of care in Europe for esophageal variceal hemorrhage in patients with liver cirrhosis, and was recently approved in France, Ireland and South Korea for the treatment of patients with HRS type 1.


Orphan Therapeutics, LLC, is a privately held drug development company dedicated to developing treatments for rare and serious diseases. It was founded in 2003 with the initial purpose to develop and seek U.S. FDA approval for its first product, LUCASSIN(R) (terlipressin), for the treatment of hepatorenal syndrome (HRS) type 1. For more information contact Stephen Zoegall, Ph.D., at Berry & Company Public Relations (212 253-8881; or visit

SOURCE Orphan Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
2. Biotest Pharmaceuticals Corporation Responds to Orphan Drug Act Announcement
3. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
4. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
5. Historic Global Vigil for AIDS Orphans Ends in New York City
6. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
7. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
8. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
9. AVANT Immunotherapeutics Announces Hart-Scott Rodino Clearance to License Cancer Vaccine to Pfizer
10. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
11. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2008 Financial Results on Wednesday, May 14, 2008 at 4:30 P.M. EST
Post Your Comments:
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
(Date:11/30/2015)... ... 30, 2015 , ... The presidential race normally deals with political issues of ... a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s hairstyle? ... than anyone wants to admit when it comes to how people are viewed by ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one ... , Their study showed that small molecule analogs that target the functions of ...
(Date:11/30/2015)... ... 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics and is ... Margulies to experience the best available orthodontic experience in the area. Dr. Margulies ... , Orthodontics is the branch of dentistry that specializes in the diagnosis, prevention, and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- IBA Molecular North America, Inc. (IBAMNA), a U.S. leader ... as of January 1, 2016, it will do business ... rebrand the company reflects a refined vision for the ... relationship with Zevacor Molecular.  Both IBAMNA and Zevacor Molecular ... Peter Burke , Vice President Sales and ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
Breaking Medicine Technology: